Lates News

According to the AI Flash News, Pacific Securities released a research report on May 2, giving a buy rating to Junshi Biosciences (688180.SH). The reasons for the rating mainly include: 1) Expanded sales revenue maintains high growth, significant improvement in operational efficiency, and cash on hand of 3 billion yuan; 2) Junshi obtained 12 indications domestically and made smooth progress in international layout; 3) Two early pipeline products entered clinical stages, with VV116 being conditionally approved for regular approval; 4) The core pipeline in 2025 has multiple catalysts. (Daily Economic News)